Generic Liquid Drug Manufacturer Providing Refunds for 340B Overcharges

The U.S. Health Resources and Services Administration (HRSA) is requiring Pharmaceutical Associates, Inc. (PAI), a South Carolina-based generic liquid drug manufacturer, to repay 340B covered entities for charges on its products above the 340B ceiling price discovered during a fiscal year 2020 audit.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.